Mayne Pharma Group Ltd. (AU:MYX) has released an update.
Mayne Pharma Group Ltd has announced the U.S. Patent and Trademark Office awarded two additional patents for its NEXTSTELLIS® oral contraceptive, extending protection until June 17, 2036. The patents strengthen the company’s intellectual property for NEXTSTELLIS®, which is showing the highest growth rate in the US branded oral contraceptive market. NEXTSTELLIS® features a unique combination of a plant-derived estrogen and a progestin, marking the first new estrogen introduced in the US in over 60 years.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.
